Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;3(5):605-9.

Aldosterone antagonism in heart failure

Alan B Miller  1
Affiliations
Review

Aldosterone antagonism in heart failure

Alan B Miller. Vasc Health Risk Manag. 2007.

Abstract

Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction. Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure. The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo. Very few of these patients were on standard therapy with beta blockade. Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone. These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pathophysiology of aldosteronone in heart failure.
See this image and copyright information in PMC

References

    1. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronic heart: A new era in the treatment of heart failure. Circulation. 1996;94:2285–96. - PubMed
    1. Juurlink DN, Mamdahi MM, Los DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Eng J Med. 2004;352:543–51. - PubMed
    1. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The Resolved Pilot Study Investigators. Circulation. 1999;100:1056–64. - PubMed
    1. Overdich HJ, Merkus FW. The metabolism in biopharmaceuticals of spironolactone in man. Rev Drug Metab Drug Interact. 1987;5:273–302. - PubMed
    1. Pitt B, Remme W, Zannad F, et al. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21. - PubMed

MeSH terms